$115,000
median · per year, annualized USD
$104,169
median · per year, annualized USD
Senior Clinical Research Associate
Senior Clinical Research Associate (CRA) - Texas or Arizona
Senior Clinical Research Associate
Sr Clinical Research Associate (CRA)
Clinical Research Associate II
Clinical Research Associate 2
Clinical Research Associate II / Sr. CRA, Eastern or Central US
Clinical Research Associate II / Sr. CRA (Pain Management), Central US
Clinical Researcher
Clinical Research Associate II - FSP
Pharmacy Manager (Pharmacist-in-Charge / PIC)
Specialty Pharmacist - 2nd Shift (1:00PM to 9:30PM EST)
Lead Compounding Pharmacist - Romeoville, IL
Pharmacist In Charge (Specialty) - Lufkin, TX
Pediatric Clinical Pharmacist
Compliance Pharmacist, Dispense & Fulfillment
Pharmacist
Superintendent Pharmacist
Lead Clinical Pharmacist
Pharmacist, Per Diem
| Company | Median | Roles |
|---|---|---|
Care Access
|
$90,000 | 16 |
Corcept Therapeutics
|
$150,175 | 2 |
Rho Inc
|
$115,000 | 2 |
Arizona Liver Health
|
$66,040 | 2 |
MapLight Therapeutics
|
$152,500 | 1 |
Ceribell, Inc
|
$133,500 | 1 |
Personalis, Inc
|
$132,500 | 1 |
Egenesisbio
|
$132,000 | 1 |
| Company | Median | Roles |
|---|---|---|
| PH Pulse Healthcare | $97,225 | 16 |
Montu UK
|
$87,536 | 11 |
Arine
|
$126,880 | 8 |
| SH Shields Health Solutions | $132,500 | 6 |
Hims & Hers
|
$110,047 | 4 |
Pharmacy2U
|
$75,299 | 4 |
Ro
|
$137,998 | 3 |
House Rx
|
$135,000 | 3 |
| Location | Median | Roles |
|---|---|---|
| London | $94,064 | 18 |
The median for Clinical Research is $115,000 per year (typically $75,000–$132,000), versus $104,169 for Pharmacist ($84,197–$130,000). That puts Clinical Research about 10% ahead at the median.
Both figures are computed live from active listings on JobsRadar and normalized to annualized USD, so Clinical Research and Pharmacist are compared on equal terms regardless of the currency each role was originally posted in. Only roles that publish a salary range feed the medians; numbers refresh every few hours as new roles post and older ones close, so this comparison reflects the market right now rather than a fixed survey. Use it as a directional benchmark when weighing one path against the other.